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Abstract
Introduction
There are numerous challenges in delivering appropriate treatment for multidrug-resistant
tuberculosis (MDR-TB) and the evidence base to guide those practices remains limited. We
present the third updated Research Agenda for the programmatic management of drug-
resistant TB (PMDT), assembled through a literature review and survey.
Methods
Publications citing the 2008 research agenda and normative documents were reviewed for
evidence gaps. Gaps were formulated into questions and grouped as in the 2008 research
agenda: Laboratory Support, Treatment Strategy, Programmatically Relevant Research,
Epidemiology, and Management of Contacts. A survey was distributed through snowball
sampling to identify research priorities. Respondent priority rankings were scored and
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summarized by mean. Sensitivity analyses explored weighting and handling of missing
rankings.
Results
Thirty normative documents and publications were reviewed for stated research needs;
these were collapsed into 56 research questions across 5 categories. Of more than 500 sur-
vey recipients, 133 ranked priorities within at least one category. Priorities within categories
included new diagnostics and their effect on improving treatment outcomes, improved diag-
nosis of paucibacillary and extra pulmonary TB, and development of shorter, effective regi-
mens. Interruption of nosocomial transmission and treatment for latent TB infection in
contacts of known MDR−TB patients were also top priorities in their respective categories.
Results were internally consistent and robust.
Discussion
Priorities retained from the 2008 research agenda include shorter MDR-TB regimens and
averting transmission. Limitations of recent advances were implied in the continued quest
for: shorter regimens containing new drugs, rapid diagnostics that improve treatment out-
comes, and improved methods of estimating burden without representative data.
Conclusion
There is continuity around the priorities for research in PMDT. Coordinated efforts to
address questions regarding shorter treatment regimens, knowledge of disease burden
without representative data, and treatment for LTBI in contacts of known DR-TB patients
are essential to stem the epidemic of TB, including DR-TB.
Introduction
Drug-resistant tuberculosis (DR-TB) threatens global TB control and is a major public health
concern. The World Health Organization (WHO) estimates that 480,000 new cases of multi-
drug-resistant tuberculosis (MDR-TB), tuberculosis resistant to at least isoniazid and rifampi-
cin, occurred in 2014.[1] Of these, an estimated 8.7% had extensively drug-resistant
tuberculosis (XDR-TB), defined as MDR- TB with additional drug resistance to at least one flu-
oroquinolone and a second-line injectable drug. Effective management of drug-resistant tuber-
culosis (DR-TB) requires prevention, case detection, care and treatment, surveillance, drug
management, and monitoring and evaluation of program performance. These activities should
be coordinated by national TB control programs, and are referred to collectively as the "pro-
grammatic management of drug-resistant tuberculosis" (PMDT).
Guidance fromWHO on PMDT has been available since 2006, and updated guidance based
on new research, technology, and expert opinion has become available over the past decade.[2–
5] Unfortunately, progress on the scale up of PMDT has been decidedly slow. Despite an
increase in the number of persons with MDR-TB detected, from 46,897 in 2009 to 122,618 in
2014, approximately 75% of TB patients estimated to have MDR-TB were still not detected in
2014.[1, 6] Treatment scale up lags far behind the Stop TB Partnership's Global Plan targets to
treat 1.6 million MDR-TB and XDR-TB patients by 2015, with only 110,803 (23.0%) of
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estimated incident cases of MDR-TB and 4,044 (8.7%) of estimated incident cases of XDR-TB
reported to be enrolled on treatment during 2014.[1] The diagnostic and treatment “gaps”
mean that many cases of MDR-TB are neither being identified nor treated, contributing to the
further spread of MDR-TB. The consequences of these gaps can be seen in regions reporting
increasing rates of MDR-TB among new TB patients.[7] Although evidence from resource-lim-
ited settings on the effectiveness and feasibility of PMDT has provided a foundation for guid-
ance, many knowledge gaps still remain.
Two previously published research agendas (2003, 2008) highlighted research gaps affecting
the operation of PMDT pilot projects, and identified research questions that needed to be
addressed in order to inform the scale up of PMDT.[8, 9] Publications citing the last research
agenda spanned all topics in the 2008 publication including Laboratory Support,[10] Epidemi-
ology,[11] Programmatically Relevant Research,[12–15] Treatment Strategy,[16–19] and Man-
agement of Contacts,[20–22] as well as those that were cross-cutting through multiple priority
areas.[23, 24] These publications included both original research articles and reviews summa-
rizing existing evidence. Here, we update the pending research questions, systematically iden-
tify new knowledge gaps, and determine the relative priority of these research questions
through a consultative process among research stakeholders in PMDT.
Methods
Development of research questions
A group consisting of members from the former Research Subgroup of the MDR-TBWorking
Group of the Stop-TB Partnership (merged with the Research Task Force of the Global Drug-
Resistant TB Initiative [GDI, http://www.stoptb.org/wg/mdrtb/]), Core Group of the GDI, and
RESIST-TB (Research Excellence to Stop TB Resistance) (http://www.resisttb.org/) prepared
the present manuscript. The group first reviewed the 2008 research agenda on PMDT to clas-
sify the previously published research priorities as still relevant and unresolved, relevant and
only partially resolved, or no longer relevant.[9] To identify additional knowledge gaps, we
reviewed resources including guidelines, documents, websites and publications published
between January 2008 and August 2013 from relevant organizations and authorities such as
the US Centers for Disease Control and Prevention (CDC), the National Institute of Allergy
and Infectious Diseases (NIAID), the WHO, European Centre for Disease Prevention and
Control (ECDC), Médecins Sans Frontières (MSF), and others (See Table 1). In addition, we
reviewed all PubMed-indexed documents that cited the 2008 publication. We extracted state-
ments about knowledge gaps and/or explicit research questions from these documents. Over-
lapping statements were consolidated and formulated into 56 research questions that were
categorized into 34 subcategories. These were organized into the 5 main research categories,
established in the 2008 research agenda on PMDT: Laboratory Support, Epidemiology,
Programmatically Relevant Research, Treatment Strategy, and Management of Contacts.[9]
From this extensive list of research questions, an online survey to establish priorities among
the questions was constructed using Qualtrics (Provo, UT).
Format and distribution of survey
The survey comprised two primary sections: 1) selection and ranking of specific research ques-
tions within each of the five main categories; and 2) global ranking of subcategories. For the
first section, respondents were instructed to select 5 priority research questions in each main
category identified in the 2008 research agenda on PMDT.[9] Within each main category, they
were asked to rank the 5 selected research questions from 1–5, with 1 being the highest priority.
Respondents could also choose to select, but not rank research questions. In the second part,
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respondents were instructed to select and rank 5 priority subcategories from the complete list
of subcategories. This second ranking served to assess internal consistency. Additionally, it pro-
vided respondents the chance to prioritize not only within a main category but acrossmain
categories.
Snowball sampling was used to select survey respondents: the survey was distributed by
email to PMDT research stakeholders including RESIST-TB, Treatment Action Group, TB
CARE I, TB TEAM, Stop TB Partnership’s New Diagnostics Working Group, the former
MDR-TBWorking Group, and GDI. These groups, in turn, shared the survey with their own
distribution lists and with other groups. The number of recipients was estimated to be at least
500.
Analysis of survey
For each main category, we designated the subset of the survey respondents who selected at
least one research question. We calculated the proportion who selected each individual ques-
tion. Questions that were selected but not ranked were recoded at the intermediate value of 3,
and any questions that were unselected by a participant were coded as 6, to reflect their priority
as lower than the lowest possible ranking for selected research questions. We then scored each
research question as the mean rank, on a scale of 1 to 6, with 1 representing the highest possible
priority and 6 the lowest. Because there were different numbers of questions in each category,
numeric priority ranking could be compared within, but not between, categories. We per-
formed two different sensitivity analyses to assess the robustness of the rankings. In one, we
excluded (rather than recoded) the questions that were not ranked (which comprised<20% of
responses). In another, we separately coded unselected questions as missing and weighted the
mean by response rate [Mean ðNþNmissÞ
N
].
Table 1. List of documents, websites, and articles citing the 2008 research agenda reviewed for state-
ments on research needs.
CDC Plan to Combat Extensively Drug Resistance Tuberculosis, Recommendations for the Federal
Tuberculosis Task Force (2009)
NIAID Research Agenda: Multidrug Resistance and Extensively Drug Resistant Tuberculosis (2007)
MSF/PIH Manual- Tuberculosis: Practical Guide for Clinicians, Nurses, Laboratory Technicians and
Medical Auxiliaries (2013)
WHO/Stop TB Operational Research Guide: Priorities in Operational Research to Improve Tuberculosis
Care and Control (2011)
The Union: Guidelines for the Clinical and Operational Management of DR-TB (2013)
STOP-TB Partnership Global Plan to Stop TB (2011–2015)
ECDC Technical Report ERLN-TB Expert Opinion on the Use of the Rapid Molecular Assays for the
Diagnosis of Tuberculosis and Detection of Drug Resistance (2013)
WHO Guidelines for the Programmatic Management of Drug-Resistance Tuberculosis Emergency Update
2008 (2008)
WHO Guidelines for the Programmatic Management of Drug-Resistance Tuberculosis 2011 Update (2011)
WHO and TDR-Priorities for Tuberculosis Research: A Report of the disease reference group on TB,
leprosy and Buruli ulcer (2013)
STOP-TB Partnership: An International Roadmap for Tuberculosis Research (2011)
TB Alliance Website
Stop TB Working Group on New Drugs Website
New Diagnostics Working Group Website
NIH RePORTER
15 Pubmed indexed articles citing the 2008 research agenda [10–24]
doi:10.1371/journal.pone.0155968.t001
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For the subcategory ranking, we included responses from individuals who completed this
section as instructed, selecting 4, 5, or 6 subcategories from the complete list of 34 subcatego-
ries. Selected subcategories were ranked on a scale of 1 to 6, with 1 as the highest priority and 6
as the lowest priority. Subcategories selected but not ranked were recoded to an intermediate
value of 3, as for the research questions within the main categories. If a respondent selected or
ranked more than 6 subcategories, we excluded the response from the analysis.
Ethics statement
Ethics approval was not sought for this study. Surveys were completed anonymously and no
data (identifiers or otherwise) were collected on respondents.
Results
We identified and reviewed 30 sources for statements on knowledge gaps in PMDT (Table 1):
15 were normative documents or websites; and a PubMed search for peer-reviewed publica-
tions that cited the 2008 research agenda returned an additional 15 sources. Over 100 calls for
research on topics related to PMDT were extracted from these documents and consolidated
into 56 distinct research questions. Since all 5 research categories from the 2008 research
agenda were judged to still be relevant, (i.e., none was thought to be completely resolved), the
unique research questions were classified across these five categories: 10 in Laboratory Support;
7 in Treatment Strategy; 18 in Programmatically Relevant Research; 13 in Epidemiology; and 8
in Management of Contacts. Survey participants selected priority questions within and across
these categories. Among more than 500 survey recipients, 133 (approximately 27%) answered
at least one question (Fig 1).
In the Laboratory Support main category, the questions “Do results of new diagnostic tests
improve patient-relevant outcomes OR treatment outcomes?” and “How can we reliably iden-
tify forms of tuberculosis that are not easily diagnosed by examination of sputum (e.g., menin-
gitis, pediatric TB, TB in HIV-coinfected persons)?” were selected as top priorities, with scores
of 3.33 and 3.69, respectively (Fig 2). These were selected over questions that focused on refin-
ing drug susceptibility testing (DST), markers of fitness, and evaluating treatment response.
In the Treatment Strategy category, the questions: “How do we develop effective and shorter
treatment regimens that can be used for special populations (e.g., pregnant/lactating women,
children, HIV-coinfected individuals)?”, “What are the optimal combinations and duration of
treatment to prevent drug resistance?” and “Is the Bangladesh regimen (a 9-month gatifloxa-
cin-based regimen) effective in countries with high prevalence of resistance to second-line
drugs (SLDs)? What modifications would be necessary?” ranked as the top priorities (scores:
2.76, 2.84, 2.87) (Fig 3). The lowest priorities in this category were questions related to optimi-
zation and further individualization of treatment with SLDs (with or without antiretroviral
therapy) and toxicity.
In the Programmatically Relevant Research category, the highest ranked research question
was “What are options for short-course treatment and how can they be used to expand
MDR-TB treatment?”. Distant second and third priorities were the questions: “What are barri-
ers to treatment initiation and completion?” (4.28) and “Which groups at risk for MDR-TB
should be targeted for DST in settings of limited resources and which diagnostic algorithms
should be used to identify patients within risk groups?”(4.49). These were all ranked in the top
5 by those who ranked at least one question, as were “Operationally, what are the best methods
to ensure optimal treatment, including guidelines; reliable drug supply; staff appropriately
trained; adequate health facilities?” with a score of 4.75 and “What infection control measures
exist with proven evidence to reduce transmission?” (4.81) (Fig 4).
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Fig 1. Survey Response.
doi:10.1371/journal.pone.0155968.g001
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In the Epidemiology category the question “What interventions are effective at reducing
nosocomial infection? What is the impact of these interventions?” was highest ranking, with a
score of 3.74. The questions “In countries without current, representative data on the burden
of drug-resistant TB, what is the burden? (How) can non-representative data be used to
improve estimates of DR-TB?” and “What ecologic or population-level characteristics predict
incidence, resistance acquisition and/or amplification, transmission, or outcomes?” were also
high ranking, with scores of 4.18 and 4.52, respectively (Fig 5). In addition, the research ques-
tion “What is the frequency of resistance to PZA, moxifloxacin, and injectables?” also arose as
a priority (score: 4.52). The topics with the fewest selections and lowest rankings included the
role of strain and resistance patterns as predictors of epidemiologic indicators.
Lastly, among 113 respondents to the Management of Contacts category, “What are optimal
drugs, combinations, and durations for latent tuberculosis infection (LTBI) in known contacts
of MDR-TB patients?” was the top priority with a score of 3.17 (Fig 6). Also high priorities
were “What are the best methods for preventing household transmission” and “What
Fig 2. Laboratory support–mean of priority ranking assigned by respondents (N = 132), 1 representing the highest priority and 6 representing
the lowest priority.
doi:10.1371/journal.pone.0155968.g002
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biomarkers can be used to distinguish infection from disease?” with scores of 3.66 and 3.74,
respectively. In contrast, topics on post-exposure vaccines, averting nosocomial transmission,
and individualization of prophylactic treatment were lower priorities.
Only 58% of respondents who initiated the survey completed the second part according to
instructions (see S1 Appendix). We note, however, that priorities selected across subcategories
were generally consistent with those within categories. Results from the Subcategory ranking
are available in the Appendix (See S2 Appendix).
Rare exceptions included “vaccines (as a strategy for management of contacts)”, which was
selected as the 3rd ranked subcategory overall while the related questions ranked in the middle
within the Management of Contacts category. How to optimize access to MDR-TB diagnosis
and treatment was selected as 4th in the Programmatically Relevant Research category and 4th
overall. Despite these exceptions, the similarity between the rankings of subcategories and
main categories supports the internal consistency of survey results. Results from the sensitivity
analyses, both when we performed the analysis with results weighted by response rate and
Fig 3. Treatment strategy—mean of priority ranking assigned by respondents (N = 126), 1 representing the highest priority and 6 representing
the lowest priority.
doi:10.1371/journal.pone.0155968.g003
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when we excluded selections that were not ranked, were similar to those from the primary
analysis.
Discussion
This third research agenda informing PMDT is the result of a multistep, systematic, consulta-
tive approach to identify current research priorities. It builds on the pioneering efforts that led
to publications in 2003 and 2008.[8, 9] For the present effort, we added an extensive literature
review and stakeholder survey to the previous strategy of identifying and grouping priorities by
the writing groups.
Certain research questions emerged consistently across categories. Shortened regimens,
which would be effective in a range of patient populations, were clearly perceived as a high pri-
ority within and across categories. This topic has been the subject of some research in the
interim, and the need for advancement in this area was noted in the 2008 research agenda and
Fig 4. Programmatically relevant research—mean of priority ranking assigned by respondents (N = 119), 1 representing the highest priority and
6 representing the lowest priority.
doi:10.1371/journal.pone.0155968.g004
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the 2011 WHO guidelines,[2, 3] the latter calling for further investigation on optimizing treat-
ment regimens, including in special populations such as children. Observational studies of
9-month regimens, variations on that known as the "Bangladesh regimen,” have been success-
fully implemented in several settings.[25–27] Moreover, the recent conditional approval of
bedaquiline and delamanid, two new anti-TB drugs [28, 29], has induced additional interest in
shortened, and now all-oral, regimens. Ongoing research efforts to advance the evidence base
in this area include the STREAM trial;[26] three trials sponsored by the Global Alliance for TB
Drug Development explore shortened regimens for DR-TB: NC-005, ClinicalTrials.gov Identi-
fier: NCT02193776; STAND, ClinicalTrials.gov Identifier: NCT02342886; and NIX-TB, Clini-
calTrials.gov Identifier: NCT02333799. Additionally, groups such as the AIDS Clinical Trials
Group through ACTG5343, and MSF through TB-PRACTECAL (ClinicalTrials.gov Identifier:
NCT02589782) and endTB, together with Partners In Health,[30, 31] are exploring shorter,
simpler regimens that depend less on second-line drugs with extensive prior use. Instead, these
efforts will use combinations of new drugs or repurposed drugs with less prior population
Fig 5. Epidemiology—mean of priority ranking assigned by respondents (N = 115), 1 representing the highest priority and 6 representing the
lowest priority.
doi:10.1371/journal.pone.0155968.g005
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exposure. Interestingly, developing effective shorter regimens—rather than reducing toxicity of
treatment—emerged as the priority within the Treatment Strategy category, despite the devel-
opment of treatment for toxicity linked to second-line drugs appearing as a gap in the 2011
WHO guidance. This may be because shortened regimens with toxicity profiles similar to the
current regimen would still be considered an advance if they are effective. Or, this preference
may reflect expectations that shorter regimens will reduce exposure to less toxic drugs (e.g.,
eliminating injectable, shortening exposure to ethionamide).
Treatment of latentMycobacterium tuberculosis infection (LTBI) in contacts of DR-TB
patients was also highlighted, as were other measures to prevent or rapidly detect active disease
—pre-exposure vaccines, averting nosocomial transmission, and active case finding. Relative to
efforts to produce shorter, more efficacious regimens and in contrast to improved LTBI treat-
ment after exposure to drug susceptible TB,[32] there has been limited activity in this domain
since the 2008 publication and the 2011 WHO guidelines[3] which also identified this research
gap and called for advances in this area. Recent exceptions include case series and observational
Fig 6. Management of contacts—mean of priority ranking assigned by respondents (N = 113), 1 representing the highest priority and 6
representing the lowest priority.
doi:10.1371/journal.pone.0155968.g006
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studies of treatment of LTBI in household contacts of patients with MDR-TB, often children,
with regimens containing fluoroquinolones.[33–37] Trials being planned at this writing
include V QUIN and TB-CHAMP, which will test levofloxacin for prophylaxis, and PHOENIx
(ACTG A5300), which is likely to test delamanid.[38, 39]
Changes from the 2008 research agenda are notable. These include a refinement of the pri-
ority placed on new DST methods. In the current research agenda, the call is for better evidence
on the impact of new methods on improved treatment outcomes. Research to date has not sup-
ported the hypothesis that introduction of rapid molecular tests (GeneXpert MTB/RIF or
GenoType MTBDR) is leading to improved treatment outcomes. [40–44] It appears unlikely
that diagnostics alone—in the absence of other interventions that improve the timely, pro-
grammatic management of MDR-TB—can realistically be expected to have an impact on out-
comes or epidemiology of MDR-TB.[42, 45] The current priorities also highlight the need for
diagnostic tools that result in improved sensitivity for traditionally difficult-to-diagnose TB
(extra pulmonary TB, TB in HIV-coinfected or pediatric populations). The emphasis on pro-
grammatic research to select algorithms for screening sub-populations for MDR-TB persists
from the 2008 research agenda, but as a relatively low priority in the area of programmatically
relevant research. Its decline in perceived importance may be because such risk profiles are
already being incorporated in algorithms that guide the use of GeneXpert MTB/RIF and other
rapid tests in populations, and, WHO guidelines released in 2011 call for universal screening
for rifampin resistance in all TB patients. Working toward this standard obviates the need for
refined identification of these risk groups.
Respondents revealed some interest in improved estimates of the prevalence of drug resis-
tance, even in the absence of fully representative national data. This may reflect the reality that
even 20 years into the project on Anti-TB Drug Resistance Surveillance, only a limited number
of countries have recent, national, representative data from surveys or ongoing surveillance of
drug resistance. This is particularly salient for the Africa region in which 19 (40%) of 47 coun-
tries have no data and only 28 (60%) countries have or are undertaking national surveys or sur-
veillance. Only 9 (20%) have relatively current data, that is, results from 2010–2014.[1] The
absence of recent representative data does not necessarily correspond to the absence of resis-
tance;[46] countries require tools for planning and treating even in the absence of such data.
[14]
Implementation
As noted, the changes in priorities since 2008 reflect, in part, exciting advances in rapid diag-
nostics—GeneXpert and GenoType MTBDRplus—and treatment options, the Bangladesh reg-
imen and new anti-TB drugs, bedaquiline and delamanid. Some changes also reflect a
pragmatism about the current state of affairs—that there would be interest in developing meth-
odologies for drawing inference from non-representative anti-TB drug resistance surveys, for
example—and the paucity of resources for TB research.[47] For the same reason, many of the
2008 priorities appear again as priorities eight years later. Also it is important to note that the
priorities emerging from these consultative efforts are not necessarily reflected in the choices
made by industry. For example, both bedaquiline and delamanid were conditionally approved
based on trials whose designs added these drugs to the currently recommended long, weak and
toxic standard of DR-TB treatment. This reflects the companies’ priority of getting the drugs
approved, and the way regulatory authorities make approval decisions. While short, all-oral
regimens emerge here as a top priority, these were not addressed in the sponsors’ trials. Fortu-
nately, non-industry researchers have begun to address these questions, frequently supported
by public funding (e.g., South African Medical Research Council, USAID, US National
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Institutes of Health, UNITAID).[31] Continued advocacy around ensuring adequate resources
for research and accelerated testing of new interventions, and support of new initiatives, such
as the 3P project, that use open-collaboration frameworks and incentives to promote regimen
development early in the clinical development of products is essential.[48] To this end, the
engagement of GDI and RESIST-TB, as well as activists, researchers, donors and policymakers
will be key to continued research advocacy.
Limitations
First, the representativeness of survey respondents is not known. The survey sought input from
an extensive list of individuals that included clinical researchers, policy makers, clinicians and
other service providers, activists, patients, and donors. Only approximately 20% of these indi-
viduals responded, and information about geographical and professional distribution of
respondents is not available. Nevertheless, since the priorities identified represent progressions
—not dramatic deviations—from those identified in the previous documents, the results are
credible as a reflection of the perspective of individuals involved in or affected by PMDT. Sec-
ond, stakeholder input was sought only on issues that were raised in the sources consulted.
Although every attempt was made to review an exhaustive body of relevant sources, other
knowledge gaps and new areas of important research that were not mentioned in the sources
reviewed were not submitted to survey respondents for ranking. This may result in a bias, espe-
cially toward applied research, which was prioritized in the previous research agenda on which
the current exercise was based. Nevertheless, the systematic, transparent, and inclusive process
that resulted in the present document represents a strength of the agenda.
Conclusion
Longstanding evidence gaps plague the scale-up of programmatic management of MDR-TB. A
systematic effort to assess the priorities for evidence necessary to expand treatment access
yielded internally consistent, robust results. Coordinated efforts to address questions regarding
shorter treatment regimens, distribution of disease where representative data do not exist, and
treatment for LTBI in household contacts of known DR-TB patients are essential to stem the
epidemic of TB, including DR-TB.
Supporting Information
S1 Appendix. Survey on research priorities in the programmatic management of DR-TB.
(PDF)
S2 Appendix. Subcategory ranking.
(PDF)
S3 Appendix. Data.
(XLSX)
Acknowledgments
Drs. Christian Lienhardt and Fraser Wares are staff members of the WHO, and Laura Jean
Podewils is a staff member at the Centers for Disease Control and Prevention. The authors
alone are responsible for the views expressed in this publication and they do not necessarily
represent the decisions or policies of the WHO or the official position of the Centers for Dis-
ease Control and Prevention. RESIST-TB’s Steering Committee includes: Grania Brigden,
Francesca Conradie, Margareth Dalcolmo, Stefan Goldberg, Martin Grobusch, Salim Hamid,
Research Agenda for Programmatic Management of DR-TB
PLOSONE | DOI:10.1371/journal.pone.0155968 May 25, 2016 13 / 16
Mark Harrington, Robert Horsburgh, Salmaan Keshavjee, Christoph Lange, Erica Lessem,
Christian Lienhardt, Carole Mitnick, Susan van den Hof, and Andy Vernon. The Core Group
of the Global Drug-Resistant Tuberculosis Initiative includes: Heather Alexander, Amy Bloom,
Sarabjit Chadha, Chen-Yuan Chiang, Daniela Cirillo, Charles Daley, Essam Elmoghazy, Jenni-
fer Furin, Agnes Gebhard, Sirinapha Wungmanee Jitimanee, Saira Khowaja, Rafael Laniado
Laborin, Andrey Maryandyshev, Fuad Mirzayev, Subrat Mohanty, Kuldeep Singh Sachdeva,
Hind Satti, Kwonjune Justin Seung, Carrie Tudor, Jacques van den Broek, and Andre Zagorski.
Author Contributions
Conceived and designed the experiments: CDM FC LJP EO SvdH C. Lange MPG. Performed
the experiments: CDM CAR GB FCMPG RH C. Lange C. Lienhardt EO LJP BS SvdH CLD
ACG FW. Analyzed the data: MH. Wrote the paper: CDM CARMH. Designed the survey to
collect data: CAR.
References
1. Global tuberculosis report 2015. Geneva: World Health Organization; 2015 (WHO/HTM/TB/2015.22).
2. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008.
Geneva: World Health Organization; 2008 (WHO/HTM/TB/2008.402).
3. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011. Geneva: World
Health Organization; 2011 (WHO/HTM/TB/2011.6).
4. Companion handbook to theWHO guidelines for the programmatic management of drug-resistant
tuberculosis. Geneva: World Health Organization; 2014. (WHO/HTM/TB/2014.11).
5. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, World Health
Organization, 2006 (WHO/HTM/TB/2006.361).
6. Global tuberculosis report 2013. Geneva: World Health Organization; 2013 (WHO/HTM/TB/2013.11)
7. Global tuberculosis report 2014. Geneva: World Health Organization; 2014 (WHO/HTM/TB/2014.08).
8. Gupta R, Espinal M. A prioritised research agenda for DOTS-Plus for multidrug-resistant tuberculosis
(MDR-TB). Int J Tuberc Lung Dis. 2003; 7(5):410–4. PMID: 12757039
9. Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, et al. Scaling up
programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoSMed.
2008; 5(7):e150. doi: 10.1371/journal.pmed.0050150 PMID: 18613746
10. Lessells RJ, Cooke GS, Newell ML, Godfrey-Faussett P. Evaluation of tuberculosis diagnostics: estab-
lishing an evidence base around the public health impact. J Infect Dis. 2011; 204 Suppl 4:S1187–95.
doi: 10.1093/infdis/jir412 PMID: 21996701
11. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, et al. Tuberculosis burden in
households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retro-
spective cohort study. Lancet. 377(9760):147–52. doi: 10.1016/S0140-6736(10)61972-1 PMID:
21145581
12. Cobelens F, van Kampen S, Ochodo E, Atun R, Lienhardt C. Research on implementation of interven-
tions in tuberculosis control in low- and middle-income countries: a systematic review. PLoSMed.
2012; 9(12):e1001358. doi: 10.1371/journal.pmed.1001358 PMID: 23271959
13. Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, et al. Scale-up of services
and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet.
375(9732):2179–91. doi: 10.1016/S0140-6736(10)60554-5 PMID: 20488521
14. Mitnick CD, Keravec J, Cohen T. Planning for the invisible: projecting resources needed to identify and
treat all patients with MDR-TB. Int J Tuberc Lung Dis. 2013; 17(4):427–8. doi: 10.5588/ijtld.13.0110
PMID: 23485374
15. Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, Diagnosis, and Treatment
of Tuberculosis in Children and Mothers: Evidence for Action for Maternal, Neonatal, and Child Health
Services. J Infect Dis. 2012.
16. Chiang C-Y, Centis R, Migliori GB. Drug-resistant tuberculosis: Past, present, future. Respirology.
2010; 15(3):413–32. doi: 10.1111/j.1440-1843.2010.01738.x PMID: 20337989
Research Agenda for Programmatic Management of DR-TB
PLOSONE | DOI:10.1371/journal.pone.0155968 May 25, 2016 14 / 16
17. Gammino VM, Taylor AB, Rich ML, Bayona J, Becerra MC, Bonilla C, et al. Bacteriologic monitoring of
multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis. 2011;
15(10):1315–22. doi: 10.5588/ijtld.10.0221 PMID: 22283887
18. Horsburgh CR, Shea KM, Phillips P, Lavalley M. Randomized clinical trials to identify optimal antibiotic
treatment duration. Trials. 2013; 14:88. doi: 10.1186/1745-6215-14-88 PMID: 23536969
19. Lienhardt C, Davies G. Methodological issues in the design of clinical trials for the treatment of multi-
drug-resistant tuberculosis: challenges and opportunities. Int J Tuberc Lung Dis. 2010; 14(5):528–37.
PMID: 20392344
20. Becerra MC, Franke MF, Appleton SC, Joseph JK, Bayona J, Atwood SS, et al. Tuberculosis in Chil-
dren Exposed at Home to Multidrug-resistant Tuberculosis. Pediatr Infect Dis J. 2013; 32(2):115–9. doi:
10.1097/INF.0b013e31826f6063 PMID: 22926210
21. Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of chil-
dren exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis. 2012; 12(6):469–
79. doi: 10.1016/S1473-3099(11)70366-8 PMID: 22373591
22. van der Werf MJ, LangendamMW, Sandgren A, Manissero D. Lack of evidence to support policy devel-
opment for management of contacts of multidrug-resistant tuberculosis patients: two systematic
reviews. Int J Tuberc Lung Dis. 2012; 16(3):288–96. doi: 10.5588/ijtld.11.0437 PMID: 22640442
23. Rylance J, Pai M, Lienhardt C, Garner P. Priorities for tuberculosis research: a systematic review. Lan-
cet Infect Dis. 2010; 10(12):886–92. doi: 10.1016/S1473-3099(10)70201-2 PMID: 21050822
24. Grange J, Mwaba P, Dheda K, Höelscher M, Zumla A. World TB Day 2010 –New innovations are
required for enhancing the global fight against Tuberculosis: the ‘Captain of all these men of death’.
Trop Med Int Health. 2010; 15(3):274–6. doi: 10.1111/j.1365-3156.2009.02462.x PMID: 20070628
25. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inex-
pensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;
182(5):684–92. doi: 10.1164/rccm.201001-0077OC PMID: 20442432
26. Nunn AJ, Rusen I, Van Deun A, Torrea G, Phillips PP, Chiang CY, et al. Evaluation of a standardized
treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis
(STREAM): study protocol for a randomized controlled trial. Trials. 2014; 15(1):353.
27. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful '9-month Ban-
gladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J
Tuberc Lung Dis. 2014; 18(10):1180–7. doi: 10.5588/ijtld.14.0100 PMID: 25216831
28. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant
tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014; 371(8):723–32. doi: 10.
1056/NEJMoa1313865 PMID: 25140958
29. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves
outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013; 41(6):1393–
400. doi: 10.1183/09031936.00125812 PMID: 23018916
30. Médecins Sans Frontières. endTB, Expand New Drug Markets for TB 2014 [November 6, 2015]. Avail-
able from: http://www.msf.org/sites/msf.org/files/1503_endtb_presdoc_new.pdf.
31. Partners in Health. PIH among Groups Bringing New TB Treatment to Those in Need 2015 [November
6, 2015]. Available from: http://www.pih.org/press/pih-among-organizations-bringing-new-tb-treatment-
to-those-in-need.
32. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of
rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365(23):2155–66. doi:
10.1056/NEJMoa1104875 PMID: 22150035
33. Seddon JA, Hesseling AC, Finlayson H, Fielding K, Cox H, Hughes J, et al. Preventive therapy for child
contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis. 2013; 57
(12):1676–84. doi: 10.1093/cid/cit655 PMID: 24065321
34. Thee S, Garcia-Prats AJ, McIlleron HM, Wiesner L, Castel S, Norman J, et al. Pharmacokinetics of
ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
Antimicrob Agents Chemother. 2014; 58(5):2948–51. doi: 10.1128/AAC.02755-13 PMID: 24550337
35. Adler-Shohet FC, Low J, Carson M, Girma H, Singh J. Management of latent tuberculosis infection in
child contacts of multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2014; 33(6):664–6. doi: 10.1097/
INF.0000000000000260 PMID: 24445837
36. Bamrah S, Brostrom R, Dorina F, Setik L, Song R, Kawamura LM, et al. Treatment for LTBI in contacts
of MDR-TB patients, Federated States of Micronesia, 2009–2012. Int J Tuberc Lung Dis. 2014; 18
(8):912–8. doi: 10.5588/ijtld.13.0028 PMID: 25199004
37. Williams B, Ramroop S, Shah P, Anderson L, Das S, Riddell A, et al. Management of pediatric contacts
of multidrug resistant tuberculosis in the United Kingdom. Pediatr Infect Dis J. 2013; 32(8):926–7.
Research Agenda for Programmatic Management of DR-TB
PLOSONE | DOI:10.1371/journal.pone.0155968 May 25, 2016 15 / 16
38. Clayden P, Collins S, Frick M, Harrington M, Horn T, Jefferys R, et al. 2015 Pipeline Report: HIV, hepati-
tis C visus (HCV), and tuberculosis (TB). Drugs, diagnostics, vaccines, preventive technologies,
research towards a cure, and immune-based and gene therapies in development New York, NY: HIV i-
Base/Treatment Action Group; 2015 [November 6, 2015]. Available from: http://i-base.info/htb/28492.
39. Network I. IMPAACT 2003B: (PHOENIx) (DAIDS ID 12041): Protecting Households on Exposure to
Newly Diagnosed Index Multidrug-Resistant TB Patients 2015 [cited 2015 December 14]. Available
from: http://impaactnetwork.org/studies/IMPAACT2003B.asp.
40. Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, et al. Time to Treatment and
Patient Outcomes among TB Suspects Screened by a Single Point-of-Care Xpert MTB/RIF at a Pri-
mary Care Clinic in Johannesburg, South Africa. PLoS ONE. 2013; 8(6):e65421. doi: 10.1371/journal.
pone.0065421 PMID: 23762367
41. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, Wood R. Characteristics and Early Out-
comes of PatientsWith Xpert MTB/RIF-Negative Pulmonary Tuberculosis Diagnosed During Screening
Before Antiretroviral Therapy. Clin Infect Dis. 2012; 54(8):1071–9. doi: 10.1093/cid/cir1039 PMID:
22318975
42. Mupfumi L, Makamure B, ChirehwaM, Sagonda T, Zinyowera S, Mason P, et al. Impact of Xpert MTB/
RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Con-
trolled Trial. Open Forum Infect Dis. 2014; 1(1):ofu038. doi: 10.1093/ofid/ofu038 PMID: 25734106
43. Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Cobelens F, et al. Impact on
Patients’ Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Fol-
low-Up of a Stepped-Wedge Randomized Clinical Trial. PLoS ONE. 2015; 10(4):e0123252. doi: 10.
1371/journal.pone.0123252 PMID: 25915745
44. Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, Kalema N, et al. Impact of Xpert MTB/RIF
testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One.
2012; 7(11):e48599. doi: 10.1371/journal.pone.0048599 PMID: 23139799
45. Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, et al. Impact of
replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-
wedge cluster-randomized trial. PLoS Med. 2014; 11(12):e1001766. doi: 10.1371/journal.pmed.
1001766 PMID: 25490549
46. Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K. Multidrug-resistant tuberculosis in chil-
dren: evidence from global surveillance. Eur Respir J. 2013; 42(3):701–7. doi: 10.1183/09031936.
00175812 PMID: 23222872
47. Frick M. Tuberculosis Research and Development: 2014 Report on Tuberculosis Research Funding
Trends, 2005–2013. Treatment Action Group Stop TB Partnership, 2014.
48. Médecins Sans Frontières. The 3P Project: A new approach to developing better treatments for TB
2015 [November 6, 2015]. Available from: http://www.msfaccess.org/spotlight-on/3p-project-new-
approach-developing-better-treatments-tb.
Research Agenda for Programmatic Management of DR-TB
PLOSONE | DOI:10.1371/journal.pone.0155968 May 25, 2016 16 / 16
